Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6241554 | 0.88 | GRM2 (0.46) | GRM2SLC9A1TLR8HRH3MCHR1 | |
| SCHEMBL17728249 | 0.88 | GRM2 (0.46) | GRM2SLC9A1TLR8HRH3MCHR1 | |
| SCHEMBL30627901 | 0.88 | GRM2 (0.46) | GRM2SLC9A1TLR8HRH3MCHR1 | |
| SCHEMBL19911456 | 0.83 | GRM2 (0.70) | GRM2SLC9A1TLR8NPC1ALDH1A1 | |
| SCHEMBL17291776 | 0.83 | GRM2 (0.43) | GRM2SLC9A1NPC1 | |
| SCHEMBL20942800 | 0.82 | GRM2 (0.41) | GRM2SLC9A1TLR8MCHR1KCNH2 | |
| SCHEMBL14785508 | 0.81 | GRM2 (0.45) | GRM2SLC9A1TLR8NPC1ALDH1A1 | |
| SCHEMBL19911457 | 0.80 | GRM2 (0.69) | GRM2SLC9A1TLR8NPC1ALDH1A1 | |
| SCHEMBL19911447 | 0.80 | SLC9A1 (0.74) | GRM2SLC9A1NPC1LMNA | |
| SCHEMBL30620226 | 0.79 | GRM2 (0.48) | GRM2SLC9A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | GRM2 2693/4885SLC9A1 341/4885TLR8 4192/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | GRM2 2693/4885SLC9A1 341/4885TLR8 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.